Literature DB >> 9001915

In vivo measurements of lead in fingerbone in active and retired lead smelters.

J Börjesson1, L Gerhardsson, A Schütz, S Mattsson, S Skerfving, K Osterberg.   

Abstract

OBJECT: The aim of this study was to determine the bone lead concentration in lead smelters and reference subjects, relate them to the lead concentration in blood (B-Pb) and urine (U-Pb), and to use the measured bone lead to calculate a biological half-life for lead in bone. METHOD AND
DESIGN: The lead concentration in the second phalanx of the left index finger (bone-Pb) was determined in vivo using an X-ray fluorescence technique. The study population comprised 89 smelters with a history of long-term exposure to lead (71 active and 18 retired) and 35 reference subjects (27 active and 8 retired) with no known occupational exposure to lead. Bone-Pb was related to the previous lead exposure, estimated as a time-integrated B-Pb (CBLI).
RESULTS: The retired smelters had the highest bone-Pb (median value 55 micrograms/g wet weight, as against 23 micrograms/g in active smelters) and 3 micrograms/g in the reference subjects. A strong positive correlation was observed between the bone-Pb and the CBLI among both active (rs = 0.73; P < 0.001) and retired (rs = 0.71; P = 0.001) smelters. The corresponding correlations between the bone-Pb and the period of employment were of the same magnitude. For retired workers, there were positive correlations between the bone-Pb and the B-Pb (rs = 0.58; P = 0.011) and U-Pb. (rs = 0.56; P = 0.02). Multiple regression analyses showed that bone-Pb was best described by the CBLI, which explained 29% of the observed variance (multiple r2) in bone-Pb in active workers and about 39% in retired workers. The estimated biological half-life of bone-Pb among active lead workers was 5.2 years (95% confidence interval 3.3-13.0 years).
CONCLUSIONS: The high bone-Pb seen in retired workers can be explained by the long exposure periods, the higher exposure levels in earlier decades, and the slow excretion of lead accumulated in bone. The importance of the skeletal lead pool as an endogenous source of lead exposure in retired smelters was indicated by the associations between the B-Pb or U-Pb, on the one hand, and the bone-Pb, on the other. In active workers, the ongoing occupational exposure was dominant. The in vivo X-ray fluorescence technique is still mainly a research tool, and more work has to be done before it can be used more widely in clinical practice. However, over the next decade we can anticipate retrospective, prospective and cross-sectional epidemiological studies in which bone lead determinations reflecting the previous lead exposure in both occupationally and nonoccupationally lead exposed populations are related to various types of adverse health outcomes. Such studies will improve our knowledge of dose-response patterns and provide data that will have an impact on hygienic threshold limit values and prevention of lead-induced diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9001915     DOI: 10.1007/s004200050122

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  3 in total

1.  Lead in finger bone, whole blood, plasma and urine in lead-smelter workers: extended exposure range.

Authors:  Andrejs Schütz; Martin Olsson; Anker Jensen; Lars Gerhardsson; Jimmy Börjesson; Sören Mattsson; Staffan Skerfving
Journal:  Int Arch Occup Environ Health       Date:  2005-01-26       Impact factor: 3.015

Review 2.  The effect of lead intoxication on endocrine functions.

Authors:  K K Doumouchtsis; S K Doumouchtsis; E K Doumouchtsis; D N Perrea
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

3.  Association between essential tremor and blood lead concentration.

Authors:  Elan D Louis; Eva C Jurewicz; LaKeisha Applegate; Pam Factor-Litvak; Michael Parides; Leslie Andrews; Vesna Slavkovich; Joseph H Graziano; Spencer Carroll; Andrew Todd
Journal:  Environ Health Perspect       Date:  2003-11       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.